Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaomeng Wang

Showing results (51-60 of 480) with videos related to

Pageof 48
Sort By:
Neoplasia (New York, N.Y.)|March 20, 2016
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer CellsXuyuan Dong, Ester Fernandez-Salas, Enxiao Li, et al.
Journal of Medicinal Chemistry|November 8, 2014
Absolute quantitative (1)h NMR spectroscopy for compound purity determinationMark Cushman, Gunda I Georg, Ulrike Holzgrabe, et al.
Journal of Chemical Information and Modeling|February 3, 2007
Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexesYipin Lu, Renxiao Wang, Chao-Yie Yang, et al.
Cancer Biology & Therapy|June 7, 2012
AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancerMelissa K Brunckhorst, Dimitry Lerner, Shaomeng Wang, et al.
Drug Discovery Today. Technologies|June 16, 2019
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A reviewChao-Yie Yang, Chong Qin, Longchuan Bai, et al.
Cell Cycle (Georgetown, Tex.)|April 17, 2008
The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosisDale Bixby, Lisa Kujawski, Shaomeng Wang, et al.
Journal of Medicinal Chemistry|February 8, 2018
Allosteric Modulators of Drug Targets Special IssueCarrie Haskell-Luevano, Gunda I Georg, Shaomeng Wang, et al.
Cell Reports|March 1, 2018
Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerAishwarya Pawar, Paradesi Naidu Gollavilli, Shaomeng Wang, et al.
Biochemical Pharmacology|September 5, 2006
Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP)Manchao Zhang, Xueliang Fang, Hongpeng Liu, et al.
Neoplasia (New York, N.Y.)|September 15, 2020
A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivoLijie Zhao, Xin Han, Jianfeng Lu, et al.
Pageof 48

Showing results (51-60 of 480) with videos related to

Sort By:
Pageof 48
Neoplasia (New York, N.Y.)|March 20, 2016
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer CellsXuyuan Dong, Ester Fernandez-Salas, Enxiao Li, et al.
Journal of Medicinal Chemistry|November 8, 2014
Absolute quantitative (1)h NMR spectroscopy for compound purity determinationMark Cushman, Gunda I Georg, Ulrike Holzgrabe, et al.
Journal of Chemical Information and Modeling|February 3, 2007
Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexesYipin Lu, Renxiao Wang, Chao-Yie Yang, et al.
Cancer Biology & Therapy|June 7, 2012
AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancerMelissa K Brunckhorst, Dimitry Lerner, Shaomeng Wang, et al.
Drug Discovery Today. Technologies|June 16, 2019
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A reviewChao-Yie Yang, Chong Qin, Longchuan Bai, et al.
Cell Cycle (Georgetown, Tex.)|April 17, 2008
The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosisDale Bixby, Lisa Kujawski, Shaomeng Wang, et al.
Journal of Medicinal Chemistry|February 8, 2018
Allosteric Modulators of Drug Targets Special IssueCarrie Haskell-Luevano, Gunda I Georg, Shaomeng Wang, et al.
Cell Reports|March 1, 2018
Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerAishwarya Pawar, Paradesi Naidu Gollavilli, Shaomeng Wang, et al.
Biochemical Pharmacology|September 5, 2006
Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP)Manchao Zhang, Xueliang Fang, Hongpeng Liu, et al.
Neoplasia (New York, N.Y.)|September 15, 2020
A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivoLijie Zhao, Xin Han, Jianfeng Lu, et al.
Pageof 48